Hypoglycemia: Market View

This reports provides a data-driven overview of the current and future competitive landscape in Hypoglycemia Therapeutics.

• In 2024 and 2029, India is estimated to have the highest number of diagnosed incident cases of hypoglycemia, representing a large portion of global cases.
• Novo Nordisk's GlucaGen (glucagon hypokit) and Eli Lilly's Glucagon had been the primary marketed glucagons for decades.
• The hypoglycemia pipeline holds 16 molecules, with no assets in the pre-registration stage, three assets in Phase III development, and another four in

Phase II.

• Over the past decade, 217 clinical trials have been conducted in hypoglycemia. The year with the most studies initiated was 2019, with 32 trials, followed by 2018 with 30 trials.
• During the past 24 months, three strategic alliances and four mergers and acquisitions involving companies developing hypoglycemia assets have been completed.

Scope

GlobalData's Hypoglycemia: Market View combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include -

• Disease Landscape
• Disease Overview
• Epidemiology Overview
• Treatment Overview
• Marketed Products Assessment
• Breakdown by Mechanism of Action, Route of Administration
• Product Profiles with Sales Forecast
• Pricing and Reimbursement Assessment
• Annual Therapy Cost
• Time to Pricing and Time to Reimbursement
• Pipeline Assessment
• Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
• Product Profiles with Sales Forecast
• Late-to-mid-stage Pipeline Drugs
• Phase Transition Success Rate and Likelihood of Approval
• Clinical Trials Assessment
• Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
• Enrolment Analytics, Site Analytics, Feasibility Analysis
• Deals Landscape
• Mergers, Acquisitions, and Strategic Alliances by Region
• Overview of Recent Deals
• Commercial Assessment
• Key Market Players
• Future Market Catalysts

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the Hypoglycemia Therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, and companies likely to impact the global Hypoglycemia Therapeutics market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories that present the maximum opportunities for consolidations, investments, and strategic partnerships.